This form contains the measure information submitted by stewards. Blank fields indicate no information was provided. Attachments also may have been submitted and are provided to reviewers. The subcriteria and most of the footnotes from the evaluation criteria are provided in Word comments within the form and will appear if your cursor is over the highlighted area. Hyperlinks to the evaluation criteria and ratings are provided in each section.

TAP/Workgroup (if utilized): Complete all yellow highlighted areas of the form. Evaluate the extent to which each subcriterion is met. Based on your evaluation, summarize the strengths and weaknesses in each section.

Note: If there is no TAP or workgroup, the SC also evaluates the subcriteria (yellow highlighted areas).

Steering Committee: Complete all pink highlighted areas of the form. Review the workgroup/TAP assessment of the subcriteria, noting any areas of disagreement; then evaluate the extent to which each major criterion is met; and finally, indicate your recommendation for the endorsement. Provide the rationale for your ratings.

Evaluation ratings of the extent to which the criteria are met
C = Completely (unquestionably demonstrated to meet the criterion)
P = Partially (demonstrated to partially meet the criterion)
M = Minimally (addressed BUT demonstrated to only minimally meet the criterion)
N = Not at all (NOT addressed; OR incorrectly addressed; OR demonstrated to NOT meet the criterion)
NA = Not applicable (only an option for a few subcriteria as indicated)

(for NQF staff use) NQF Review #: 0113 NQF Project: Surgery Endorsement Maintenance 2010

<table>
<thead>
<tr>
<th>MEASURE DESCRIPTIVE INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>De.1 Measure Title: Participation in a Systematic Database for Cardiac Surgery</td>
</tr>
<tr>
<td>De.2 Brief description of measure: Participation in a clinical database with broad state, regional, or national representation, that provides regular performance reports based on benchmarked data</td>
</tr>
<tr>
<td>1.1-2 Type of Measure: Structure/management</td>
</tr>
<tr>
<td>De.3 If included in a composite or paired with another measure, please identify composite or paired measure</td>
</tr>
<tr>
<td>De.4 National Priority Partners Priority Area: Safety</td>
</tr>
<tr>
<td>De.5 IOM Quality Domain: Safety</td>
</tr>
<tr>
<td>De.6 Consumer Care Need: Getting better</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CONDITIONS FOR CONSIDERATION BY NQF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Four conditions must be met before proposed measures may be considered and evaluated for suitability as voluntary consensus standards:</td>
</tr>
<tr>
<td>A. The measure is in the public domain or an intellectual property (measure steward agreement) is signed. Public domain only applies to governmental organizations. All non-government organizations must sign a measure steward agreement even if measures are made publicly and freely available.</td>
</tr>
<tr>
<td>A.1 Do you attest that the measure steward holds intellectual property rights to the measure and the right to use aspects of the measure owned by another entity (e.g., risk model, code set)? Yes</td>
</tr>
<tr>
<td>A.2 Indicate if Proprietary Measure (as defined in measure steward agreement):</td>
</tr>
<tr>
<td>A.3 Measure Steward Agreement: Agreement will be signed and submitted prior to or at the time of measure submission</td>
</tr>
<tr>
<td>A.4 Measure Steward Agreement attached: STS Measure Steward Agreement. Fully Executed.pdf</td>
</tr>
<tr>
<td>B. The measure owner/steward verifies there is an identified responsible entity and process to maintain and update the measure on a schedule that is commensurate with the rate of clinical innovation, but at least</td>
</tr>
</tbody>
</table>

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable
every 3 years. Yes, information provided in contact section

C. The intended use of the measure includes both public reporting and quality improvement.

<table>
<thead>
<tr>
<th>Purpose:</th>
<th>C</th>
<th>Y</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>«purpose_additional»</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>«purpose_additional_other»</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D. The requested measure submission information is complete. Generally, measures should be fully developed and tested so that all the evaluation criteria have been addressed and information needed to evaluate the measure is provided. Measures that have not been tested are only potentially eligible for a time-limited endorsement and in that case, measure owners must verify that testing will be completed within 12 months of endorsement.

<table>
<thead>
<tr>
<th>Testing:</th>
<th>Yes, fully developed and tested</th>
</tr>
</thead>
</table>

D.2 Have NQF-endorsed measures been reviewed to identify if there are similar or related measures? Yes

(for NQF staff use) Have all conditions for consideration been met?

Staff Notes to Steward (if submission returned):

Staff Notes to Reviewers (issues or questions regarding any criteria):

Staff Reviewer Name(s):

---

TAP/Workgroup Reviewer Name:

Steering Committee Reviewer Name:

1. IMPORTANCE TO MEASURE AND REPORT

Extant to which the specific measure focus is important to making significant gains in health care quality (safety, timeliness, effectiveness, efficiency, equity, patient-centeredness) and improving health outcomes for a specific high impact aspect of healthcare where there is variation in or overall poor performance.

Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria. (evaluation criteria)

1a. High Impact

(for NQF staff use) Specific NPP goal:

1a.1 Demonstrated High Impact Aspect of Healthcare: Affects large numbers, High resource use, Patient/societal consequences of poor quality

1a.2

1a.3 Summary of Evidence of High Impact: The STS Adult Cardiac Surgery Database captures detailed clinical data on adults undergoing cardiac surgical procedures performed by participants throughout the United States. The collection and analysis of data over a 20-year period has been shown to improve patient outcomes, primarily through feedback provided by center-specific reports that allow participants to evaluate critically their own local results and to compare their own local results with contemporary national risk-adjusted benchmarks.

In fact, the very act of participation in a systematic database for cardiac surgery has been shown to increase compliance with process measures (Ferguson [1]). Furthermore, the increase in compliance with these process measures will improve outcome (Peterson [2]). Thus, outcomes can be improved by participation in a multicenter data collection and feedback program that provides benchmarking relative to peers and uses process and outcome measures.

Thus, the very act of participation in a multi-institutional database will also facilitate quality improvement.


<table>
<thead>
<tr>
<th>1a</th>
<th>C</th>
<th>P</th>
<th>M</th>
<th>N</th>
</tr>
</thead>
</table>


1b. Opportunity for Improvement

1b.1 Benefits (improvements in quality) envisioned by use of this measure: The very act of participation in a systematic database for cardiac surgery has been shown to increase compliance with process measures (Ferguson). Furthermore, the increase in compliance with these process measures will improve outcome (Peterson). Thus, outcomes can be improved by participation in a multicenter data collection and feedback program that provides benchmarking relative to peers and uses process and outcome measures. Thus, the very act of participation in a multi-institutional database will also facilitate quality improvement.

The STS Adult Cardiac Surgery Database captures detailed clinical data on adults undergoing cardiac surgical procedures performed by participants throughout the United States. The collection and analysis of data over a 20-year period has been shown to improve patient outcomes, primarily through feedback provided by center-specific reports that allow participants to evaluate critically their own local results and to compare their own local results with contemporary national risk-adjusted benchmarks.

1b.2 Summary of data demonstrating performance gap (variation or overall poor performance) across providers:
98% (925/942) of participants who actively submitted data for 2008 maintained their activity in 2009.

Among 942 participants who submitted at least one record with surgery data during 2008, 925 of these also submitted at least one record with a surgery date during 2009. Thus, 98% of participants who actively submitted data for 2008 maintained their activity in 2009.

The total number participants who submitted at least one record in 2009 is 973.

Approximately 90% of cardiac surgery centers in the US participate in the STS Adult Cardiac Surgery Database.

1b.3 Citations for data on performance gap:
Dates: January 1, 2008-December 31, 2009

Count of participants in the STS Adult Cardiac Surgery Database in 2008 vs. 2009.

1b.4 Summary of Data on disparities by population group:
N/A

1b.5 Citations for data on Disparities:
N/A

1c. Outcome or Evidence to Support Measure Focus

1c.1 Relationship to Outcomes (For non-outcome measures, briefly describe the relationship to desired outcome. For outcomes, describe why it is relevant to the target population): The desired outcome of compliance with this metric is to increase the number of cardiac surgeons and cardiac surgical programs that participate in multicenter data collection and feedback program that provide benchmarking relative to peers and uses process and outcome measures. Participation in such initiatives has been shown to improve patient outcome.

1c.2-3. Type of Evidence: Observational study, Expert opinion, Systematic synthesis of research, Other

Clinical results from approximately 90% of cardiac surgery centers in the US
1c.4 **Summary of Evidence** (as described in the criteria; for outcomes, summarize any evidence that healthcare services/care processes influence the outcome):

The very act of participation in a systematic database for cardiac surgery has been shown to increase compliance with process measures.

Reference:

The increase in compliance with these process measures will improve outcome.

Reference:

1c.5 **Rating of strength/quality of evidence** (also provide narrative description of the rating and by whom):

1c.6 **Method for rating evidence:**

1c.7 **Summary of Controversy/Contradictory Evidence:**

1c.8 **Citations for Evidence (other than guidelines):**

1c.9 **Quote the Specific guideline recommendation (including guideline number and/or page number):**

N/A

1c.10 **Clinical Practice Guideline Citation:** n/a

1c.11 **National Guideline Clearinghouse or other URL:** n/a

1c.12 **Rating of strength of recommendation** (also provide narrative description of the rating and by whom):

n/a

1c.13 **Method for rating strength of recommendation** (If different from USPSTF system, also describe rating and how it relates to USPSTF):

n/a

1c.14 **Rationale for using this guideline over others:**

n/a

TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Importance to Measure and Report?

Steering Committee: Was the threshold criterion, Importance to Measure and Report, met?

Rationale:
2. SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. *(evaluation criteria)*

<table>
<thead>
<tr>
<th>Eval Rating</th>
</tr>
</thead>
</table>

2a. MEASURE SPECIFICATIONS

**S.1** Do you have a web page where current detailed measure specifications can be obtained?

**S.2** If yes, provide web page URL:

### 2a. Precisely Specified

<table>
<thead>
<tr>
<th><strong>2a.1 Numerator Statement</strong> <em>(Brief, text description of the numerator - what is being measured about the target population, e.g. target condition, event, or outcome):</em>&lt;br&gt;Does the facility participate in a clinical database with broad state, regional, or national representation, that provides regular performance reports based on benchmarked data? <em>(y/n)</em></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2a.2 Numerator Time Window</strong> <em>(The time period in which cases are eligible for inclusion in the numerator):</em>&lt;br&gt;12 months</td>
</tr>
<tr>
<td><strong>2a.3 Numerator Details</strong> <em>(All information required to collect/calculate the numerator, including all codes, logic, and definitions):</em>&lt;br&gt;Participation in a clinical database with broad state, regional, or national representation, that provides regular performance reports based on benchmarked data. Participation in the STS Adult Cardiac Surgery Database, for example, is initiated by the surgeons and/or hospital and is defined as quarterly submission of 100% of cases via an approved software system to the Duke Clinical Research Institute, the data repository for the three STS Databases. STS’s audit cross-checks submitted cases against hospital logs to assure all cases have been captured.</td>
</tr>
<tr>
<td><strong>2a.4 Denominator Statement</strong> <em>(Brief, text description of the denominator - target population being measured):</em>&lt;br&gt;N/A</td>
</tr>
<tr>
<td><strong>2a.5 Target population gender:</strong> Female, Male</td>
</tr>
<tr>
<td><strong>2a.6 Target population age range:</strong> 18 years or older on date of encounter</td>
</tr>
<tr>
<td><strong>2a.7 Denominator Time Window</strong> <em>(The time period in which cases are eligible for inclusion in the denominator):</em>&lt;br&gt;n/a</td>
</tr>
<tr>
<td><strong>2a.8 Denominator Details</strong> <em>(All information required to collect/calculate the denominator - the target population being measured - including all codes, logic, and definitions):</em></td>
</tr>
<tr>
<td><strong>2a.9 Denominator Exclusions</strong> <em>(Brief text description of exclusions from the target population):</em></td>
</tr>
<tr>
<td><strong>2a.10 Denominator Exclusion Details</strong> <em>(All information required to collect exclusions to the denominator, including all codes, logic, and definitions):</em></td>
</tr>
<tr>
<td><strong>2a.11 Stratification Details/Variables</strong> <em>(All information required to stratify the measure including the stratification variables, all codes, logic, and definitions):</em>&lt;br&gt;N/A</td>
</tr>
<tr>
<td><strong>2a.12-13 Risk Adjustment Type:</strong> No risk adjustment necessary</td>
</tr>
<tr>
<td><strong>2a.14 Risk Adjustment Methodology/Variables</strong> <em>(List risk adjustment variables and describe conceptual models, statistical models, or other aspects of model or method):</em>&lt;br&gt;N/A</td>
</tr>
</tbody>
</table>

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable
| 2a.15-17 | Detailed risk model available Web page URL or attachment: |
| 2a.18-19 | Type of Score: Categorical |
| 2a.20 | Interpretation of Score: Passing score defines better quality |
| 2a.21 | Calculation Algorithm (Describe the calculation of the measure as a flowchart or series of steps): N/A |
| 2a.22 | Describe the method for discriminating performance (e.g., significance testing): |
| 2a.23 | Sampling (Survey) Methodology If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate): N/A |
| 2a.24 | Data Source (Check the source(s) for which the measure is specified and tested) Registry data |
| 2a.25 | Data source/data collection instrument (Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.): STS Adult Cardiac Surgery Database - Version 2.73 |
| 2a.29-31 | Data dictionary/code table web page URL or attachment: URL http://www.sts.org/documents/pdf/ndb2010/STSAultCVDataSpecificationsV2_7_20101021.pdf -- an updated version will be made available on the STS Website in mid-December of 2010 |
| 2a.32-35 | Level of Measurement/Analysis (Check the level(s) for which the measure is specified and tested) Facility/Agency, Population: Counties or cities, Population: National, Population: Regional/network |
| 2a.36-37 | Care Settings (Check the setting(s) for which the measure is specified and tested) Hospital |
| 2a.38-41 | Clinical Services (Healthcare services being measured, check all that apply) Clinicians: Physicians (MD/DO) |

**TESTING/ANALYSIS**

2b. Reliability testing

2b.1 Data/sample (description of data/sample and size): As of December 31, 2009, the STS Adult Cardiac Surgery Database had 1,004 Participants who represented 1,020 hospitals in the United States. (An STS Database Participant is either a “practice group of cardiothoracic surgeons” or an individual cardiothoracic surgeon.) The 2008 American Hospital Association Annual Survey reported that 1,088 hospitals perform cardiac surgery in adults in the United States; therefore, STS believes that current STS-participating hospitals represent over 90% of hospitals that provide adult cardiac surgery in the United States.

The STS Adult Cardiac Surgery Database captures detailed clinical data on adults undergoing cardiac surgical procedures performed by participants throughout the United States. The collection and analysis of data over a 20-year period has been shown to improve patient outcomes, primarily through feedback provided by center-specific reports that allow participants to evaluate critically their own local results and to compare their own local results with contemporary national risk-adjusted benchmarks. Using risk-adjusted data from the STS Adult Cardiac Surgery Database, STS has created numerous statistical risk-adjustment models for several common cardiac surgical operations for mortality and a variety of complications. The STS Database has also served as the basis for the development of performance measures that have been endorsed by the National Quality Forum.
2b.2 **Analytic Method** *(type of reliability & rationale, method for testing):*

2b.3 **Testing Results** *(reliability statistics, assessment of adequacy in the context of norms for the test conducted):*

### 2c. Validity testing

2c.1 **Data/sample** *(description of data/sample and size):* STS Adult Cardiac Surgery Database

Audits conducted in 2010, all cases performed in 2009; N = 40 randomly selected sites participating in the STS Adult Cardiac Surgery Database

2c.2 **Analytic Method** *(type of validity & rationale, method for testing):*

Participating sites are randomly selected for participation in STS Adult Cardiac Surgery Database Audit, which is designed to evaluate the accuracy, consistency, and comprehensiveness of data collection and ultimately validate the integrity of the data contained in the database. The Iowa Foundation for Medical Care (IFMC), the quality improvement organization for Iowa and Illinois, has conducted audits on behalf of STS since 2006.

Each year, the IFMC conducts audits at randomly selected sites throughout the country and tracks the individual agreement rates by variable and by year. More specifically, for each site, agreement rates are calculated for 73 individual elements. In addition, aggregate agreement rates for each element, variable category (e.g., pre-operative risk factors, previous interventions, etc), and overall for all categories are calculated for all sites. While this is not region specific, it is data point specific and comparison agreement rates confirm the improvement over time as well as the consistency.

In addition, validity was confirmed and is regularly assessed by an expert panel of thoracic surgeons assembled by the STS Adult Cardiac Surgery Database Task Force, the STS Task Force on Quality Initiatives and the STS Workforce on National Databases.

2c.3 **Testing Results** *(statistical results, assessment of adequacy in the context of norms for the test conducted):*

### 2d. Exclusions Justified

2d.1 **Summary of Evidence supporting exclusion(s):**

2d.2 **Citations for Evidence:**

2d.3 **Data/sample** *(description of data/sample and size):*

2d.4 **Analytic Method** *(type analysis & rationale):*

2d.5 **Testing Results** *(e.g., frequency, variability, sensitivity analyses):*

### 2e. Risk Adjustment for Outcomes/ Resource Use Measures

2e.1 **Data/sample** *(description of data/sample and size):* N/A

2e.2 **Analytic Method** *(type of risk adjustment, analysis, & rationale):*
2e.3 Testing Results (*risk model performance metrics*):

2e.4 If outcome or resource use measure is not risk adjusted, provide rationale:

2f. Identification of Meaningful Differences in Performance

2f.1 Data/sample from Testing or Current Use (*description of data/sample and size*): Among 942 participants who submitted at least one record with surgery data during 2008, 925 of these also submitted at least one record with a surgery date during 2009. Thus, 98% of participants who actively submitted data for 2008 maintained their activity in 2009.

The total number participants who submitted at least one record in 2009 is 973.

Approximately 90% of cardiac surgery centers in the US participate in the STS Adult Cardiac Surgery Database.

2f.2 Methods to identify statistically significant and practically/meaningfully differences in performance (*type of analysis & rationale*):

2f.3 Provide Measure Scores from Testing or Current Use (*description of scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance*):

The evidence connecting improved quality with participation in a systematic national database is inferred from published accounts of improved quality following participation in the STS Adult Cardiac Surgery Database and other national databases. “It appears that the routine feedback of risk-adjusted data on local performance provided by these programs heightens awareness and leads to self-examination and self-assessment, which in turn improves quality and outcomes. This general quality improvement template should be considered for application in other settings beyond cardiac surgery.” [1]

“The Society of Thoracic Surgeons National Cardiac Surgery Database allows subscribing institutions to perform sophisticated patient risk assessment using traditional statistical tools and a newly developed risk model of operative mortality. ...The risk model has proven to be a reliable tool for predicting the probability of operative death in an individual patient and may be valuable in both patient counseling and medical decision making. Large multi-institutional databases of this type are key ingredients of modern operative risk assessment. A database containing a broad national experience of this type can represent an aggregate experience that may well approximate a universally accepted standard of care.” [2]


2g. Comparability of Multiple Data Sources/Methods

2g.1 Data/sample (*description of data/sample and size*): N/A

2g.2 Analytic Method (*type of analysis & rationale*):

2g.3 Testing Results (*e.g., correlation statistics, comparison of rankings*):

2h. Disparities in Care

2h.1 If measure is stratified, provide stratified results (*scores by stratified categories/cohorts*): N/A
### 2h.2 If disparities have been reported/identified, but measure is not specified to detect disparities, provide follow-up plans:

<table>
<thead>
<tr>
<th>TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Scientific Acceptability of Measure Properties?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Steering Committee: Overall, to what extent was the criterion, Scientific Acceptability of Measure Properties, met?</strong></td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
</tr>
</tbody>
</table>

#### 3. USABILITY

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. *(evaluation criteria)*

**3a. Meaningful, Understandable, and Useful Information**

3a.1 **Current Use:** In use

3a.2 **Use in a public reporting initiative (disclosure of performance results to the public at large)** *(If used in a public reporting initiative, provide name of initiative(s), locations, Web page URL(s). If not publicly reported, state the plans to achieve public reporting within 3 years):*

- **Currently being considered for NQF endorsement, the STS CABG Composite Score is a multidimensional performance measure comprised of four domains consisting of 11 individual NQF-endorsed cardiac surgery metrics:**
  1. Operative Care--use of the internal mammary artery;
  2. Perioperative Medical Care (use of preoperative beta blockade; discharge beta blockade, antiplatelet agents, and lipid-lowering agents--an “all-or-none” measure);
  3. Risk-adjusted Operative Mortality; and
  4. Risk-Adjusted Postoperative Morbidity (occurrence of postoperative stroke, renal failure, prolonged ventilation, re-exploration, or deep sternal wound infection--an “any-or-none” measure).

- **Composite star ratings are presented on the STS website, www.sts.org/publicreporting and in the health section of the Consumers Union website, www.ConsumerReportsHealth.org.**

- **Participation in a systematic database is implicitly met, as only participants in the STS database are eligible for a composite score.**

3a.3 **If used in other programs/initiatives** *(If used in quality improvement or other programs/initiatives, name of initiative(s), locations, Web page URL(s). If not used for QI, state the plans to achieve use for QI within 3 years):*

3a.4 **Data/sample** *(description of data/sample and size):* See 3a.6 below

3a.5 **Methods** *(e.g., focus group, survey, QI project):*

3a.6 **Results** *(qualitative and/or quantitative results and conclusions):*

- **Please see attached file**

#### 3b/3c. Relation to other NQF-endorsed measures

3b.1 **NQF # and Title of similar or related measures:** N/A

(for NQF staff use) **Notes on similar/related endorsed or submitted measures:**
3b. Harmonization
If this measure is related to measure(s) already endorsed by NQF (e.g., same topic, but different target population/setting/data source or different topic but same target population):

3b.2 Are the measure specifications harmonized? If not, why?
N/A; however, data definitions and key elements have been established by a multi-societal writing committee called the “ACCF/AHA Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards” with representatives from each of the following organizations:

- Agency for Healthcare Research and Quality
- American College of Cardiology
- American College of Chest Physicians
- American College of Emergency Physicians
- American College of Physicians
- American College of Preventative Medicine
- American Heart Association
- American Medical Association
- Centers for Disease Control and Prevention
- Emergency Nurses Association
- Food and Drug Administration
- Joint Commission on Accreditation of Healthcare Organizations
- National Association of Emergency Medical Technicians
- National Association of EMS Physicians
- National Heart, Lung, and Blood Institute
- Preventive Cardiovascular Nurses Association
- Society for Academic Emergency Medicine
- Society of Chest Pain Centers and Providers
- Society of General Internal Medicine
- Society of Thoracic Surgeons

3c. Distinctive or Additive Value

3c.1 Describe the distinctive, improved, or additive value this measure provides to existing NQF-endorsed measures:
n/a

5.1 If this measure is similar to measure(s) already endorsed by NQF (i.e., on the same topic and the same target population), Describe why it is a more valid or efficient way to measure quality:
n/a

TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Usability?

Steering Committee: Overall, to what extent was the criterion, Usability, met?
Rationale:

4. FEASIBILITY

Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)

4a. Data Generated as a Byproduct of Care Processes

4a.1-2 How are the data elements that are needed to compute measure scores generated?
Data generated as byproduct of care processes during care delivery (Data are generated and used by healthcare personnel during the provision of care, e.g., blood pressure, lab value, medical condition), Coding/abstraction performed by someone other than person obtaining original information (E.g., DRG, ICD-9 codes on claims, chart abstraction for quality measure or registry)

4b. Electronic Sources
4b.1 Are all the data elements available electronically? *(elements that are needed to compute measure scores are in defined, computer-readable fields, e.g., electronic health record, electronic claims)*  
Yes

4b.2 If not, specify the near-term path to achieve electronic capture by most providers.

4c. Exclusions

4c.1 Do the specified exclusions require additional data sources beyond what is required for the numerator and denominator specifications?  
No

4c.2 If yes, provide justification.

4d. Susceptibility to Inaccuracies, Errors, or Unintended Consequences

4d.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measure and describe how these potential problems could be audited. If audited, provide results.  
This measure may be susceptible to human error (i.e., recording the measure inaccurately or not at all).

When data collection on this measure is done through participation in the STS Adult Cardiac Surgery Database, an auditing strategy is in place.

Both STS and the Duke Clinical Research Institute have a list of database participants making participation in the STS Adult Cardiac Surgery Database easy to track.

Each participant is responsible for the quality and accuracy of the data they submit to the database. The participant agrees to the following quality control measures in the participation agreement:

i) Participant hereby warrants that all data submitted for inclusion in the STS National Database will be accurate and complete, and acknowledges that such data may be subject to independent audit. Participant will use its best efforts to address any data or related deficiencies identified by the independent data warehouse service provider and agrees to cooperate with and assist STS and its designees in connection with the performance of any independent audit.

ii) Participant warrants that it will take all reasonable steps to avoid the submission of duplicative data for inclusion in the STS National Database, including but not limited to apprising the Director of the STS National Database and the independent data warehouse service provider about any other Participation Agreements in which an individual cardiothoracic surgeon named above or on Schedule A attached hereto (as amended from time to time) is also named.

STS audited for these potential problems during testing.

4e. Data Collection Strategy/Implementation

4e.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data/missing data, timing/frequency of data collection, patient confidentiality, time/cost of data collection, other feasibility/implementation issues:

4e.2 Costs to implement the measure *(costs of data collection, fees associated with proprietary measures)*:

Data Collection:  
There are no direct costs to collect the data for this measure. Costs to develop the measure included volunteer cardiothoracic surgeon time, STS staff time, and DCRI statistician and project management time.

Other fees:  
STS Adult Cardiac Surgery Database participants (single cardiothoracic surgeons or a group of surgeons) pay
annual participant fees of $2,950 or $3,700, depending on whether participants are STS members (or whether the majority of surgeons in a group are STS members). As a benefit of STS membership, STS members are charged the lesser of the two fees.

4e.3 Evidence for costs:

4e.4 Business case documentation:

TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Feasibility?

Steering Committee: Overall, to what extent was the criterion, Feasibility, met?

Rationale:

<table>
<thead>
<tr>
<th>C</th>
<th>P</th>
<th>M</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RECOMMENDATION

(for NQF staff use) Check if measure is untested and only eligible for time-limited endorsement.

Steering Committee: Do you recommend for endorsement?

Comments:

<table>
<thead>
<tr>
<th>Y</th>
<th>N</th>
<th>A</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CONTACT INFORMATION

Co.1 Measure Steward (Intellectual Property Owner)
Co.1 Organization
Society of Thoracic Surgeons, 633 North Saint Clair Street, Suite 2320, Chicago, Illinois, 60611

Co.2 Point of Contact
Jane, Han, MSW, jhan@sts.org, 312-202-5856.

Measure Developer If different from Measure Steward
Co.3 Organization
Society of Thoracic Surgeons, 633 North Saint Clair Street, Suite 2320, Chicago, Illinois, 60611

Co.4 Point of Contact
Jane, Han, MSW, jhan@sts.org, 312-202-5856.

Co.5 Submitter If different from Measure Steward POC
Jane, Han, MSW, jhan@sts.org, 312-202-5856., Society of Thoracic Surgeons

Co.6 Additional organizations that sponsored/participated in measure development

ADDITIONAL INFORMATION

Workgroup/Expert Panel involved in measure development
Ad.1 Provide a list of sponsoring organizations and workgroup/panel members’ names and organizations. Describe the members’ role in measure development.
Members of the STS Task Force on Quality Initiatives provide surgical expertise as needed. The STS Workforce on National Databases meets at the STS Annual Meeting and reviews the measures on a yearly basis. Changes or updates to the measure will be at the recommendation of the Workforce.

Ad.2 If adapted, provide name of original measure:
Ad.3-5 If adapted, provide original specifications URL or attachment

Measure Developer/Steward Updates and Ongoing Maintenance
Ad.6 Year the measure was first released: 2004
Ad.7 Month and Year of most recent revision: 12, 2010
| Ad.8 What is your frequency for review/update of this measure? | annually |
| Ad.9 When is the next scheduled review/update for this measure? | 2011 |
| Ad.10 Copyright statement/disclaimers: | |
| Ad.11 -13 Additional Information web page URL or attachment: | Attachment Section 3a.6.pdf |
| Date of Submission (MM/DD/YY): | 03/31/2011 |
Section 3a.6

Although formal testing of interpretability has not been performed, this measure has been used and reported for STS Adult Cardiac Surgery database participants since 2007. Current report presentation and interpretation manuals are presented below. These materials are updated as needed based upon feedback from database participants.

1) Report Overview and Interpretation Manual:

The NQF Measures Report

a. Organization
This report section is separated into three areas corresponding to: 1) NQF volume measures, 2) NQF process measures, and 3) NQF outcomes measures, in that order. The header at the top of each page references the report section for that page. Each NQF measure is presented on a single row in the section. Tabular data are on the left-hand side of each page and a standard graphic representation is shown on the right-hand side.

b. Statistical Calculation and Details – NQF Measures

Time period: This report section contains information on the individual STS participant and overall STS performance for the most recent 12 months for volume, process and CABG outcomes measures and the most recent 60 months for Valve and Valve + CABG outcomes. The 5 years (60 months) of performance for outcomes involving Valve procedures is necessary due to smaller sample sizes.

Volume Measures: The NQF report provides average annual case volumes data for three surgery categories: i) Isolated CABG, ii) Valve without CABG, and iii) combined CABG + Valve. Definitions of the three surgery categories are provided in Table 2 of this NQF Report Overview. For each type of surgery, the participant’s annualized volume is calculated as:

\[
\text{Participant Annualized Volume} = 12 \times (\# \text{ of surgeries}) / (\# \text{ of months})
\]

where (\# of surgeries) denotes the number of surgeries of the specified type performed by the participant during the specified time period, and (\# of months) is the number of months during the specified time period for which the participant submitted at least one cardiac surgery of any type. The intent of calculating “annualized” volumes is to adjust for participants who participated in the database for fewer months than the time period specified. For participants who participated in the database and submitted cases every month during 2006, the annualized volume for 2006 is simply the total number of cases.

The STS Average Annualized Volume is the average value of all of the participant annualized volumes across the entire population of STS participants. The Participant Percentile indicates the percent of STS participants whose annualized volumes are less than, or equal to, your own. Higher percentiles indicate higher volumes in relation to other STS participant sites. The Distribution of Participant Values shows the range and percentiles of the distribution of participant annualized volumes across all database participants. For example, 90% of participants have annualized volumes less than or equal to the value marked “90th percentile.”
Confidence intervals are not provided for volume measures, as volume is known with certainty and is not estimated.

**Process Measures:** The NQF process measures provide data on the frequency of usage of five therapies among subsets of Isolated CABG patients. The therapies are: i) preoperative beta blockade therapy, ii) use of IMA, iii) discharge anti-platelet medication, iv) discharge beta blockade therapy, and v) discharge anti-lipid medication. The patient population for each measure differs, in accordance with the NQF specifications (see Table 2 of this NQF Report Overview for details). The number of Eligible Procedures is the number of cases performed by the participant during the specified time period who meet the eligibility requirements to be included in the calculations when summarizing the participant’s data. *Beginning with the 2008 Harvest 3 report (covering the procedure time period through 6/30/2008), STS implementation of NQF medication process measures using data version 2.61 excludes records for which the medication was contraindicated/not indicated from the eligible population.* The main summary statistic, Participant Usage, is the percent of eligible Isolated CABG cases during the specified time period for which the patient received the specified therapy. The Overall STS Usage is the percent of all eligible patients in the entire STS population during the specified time period who received the specified therapy. *In calculating these percentages, missing data are treated as a “No”, emphasizing the importance of having complete data in these fields.*

The Participant Percentile indicates the percent of STS participants who applied the therapy in their respective populations less frequently than or as frequently as did your institution. The Distribution of Participant Values shows the range and percentiles of the distribution of participant usage across all participants in the database. For example, 90% of participants use the therapy less frequently than the amount indicated by the “90th percentile”. A bar identified as “Participant” indicates the point estimate and limits of a 95% Confidence Interval (CI) for the participant’s usage of therapy. The underlying parameter being estimated is the long-run usage rate that would be observed in a large sample of patients. The 95% CI indicates the range of usage rates that are consistent with the data in light of sampling variability.

**Outcomes Measures:** The NQF outcomes data provide risk-adjusted analyses of mortality and morbidity for Isolated CABG surgery as well as risk-adjusted operative mortality for Isolated AVR, Isolated MVR, AVR+CABG, and MVR+CABG. The main summary statistic provided is the Participant’s Estimated Odds Ratio (OR) based on a hierarchical logistic regression analysis. The OR measures the impact that a participant’s performance level has on a patient’s probability of experiencing an adverse outcome. The interpretation is similar to that of an O/E ratio (see the Risk-Adjusted Results: Overview portion of the General Report Overview for details on STS risk adjustment). An OR greater than 1.0 implies that the participant increases a patient’s risk of experiencing the outcome, relative to an “average” STS participant. An OR less than 1.0 implies that the participant decreases a patient’s risk of experiencing the outcome, relative to an “average” STS participant. Each measure is calculated among patients undergoing surgery of the type specified during the time period specified who additionally meet certain eligibility requirements. The column labeled Eligible Procedures indicates the number of patients who met the inclusion criteria to be included in the analysis for the indicated measure. The Participant Percentile is the percent of STS participants who have an estimated OR that is greater than or equal to your estimated OR. Note that this is different than performance percentiles for process measures, where the percentile indicates the percentage of STS
participants with performance that is less than the specified number. This simply reflects the fact that high process compliance is desirable, whereas a high OR is undesirable.

The Observed Participant Rate is the percent of eligible patients who experienced the specified outcome. Unlike the participant estimated OR, the observed participant rate is not risk-adjusted. The estimated OR is the main summary statistic for summarizing the NQF measure in this report.

The Distribution of Participant Values shows the range and percentiles of the distribution of estimated Odds Ratios across all STS participants. For example, 90% of STS participants have an OR greater than the value indicated by the “90th percentile.” The line that extends to the left and right of the Participant Value indicates the lower and upper limits of a 95% Confidence Interval (CI) surrounding the participant’s estimated OR.

c. Technical Notes

Calculation of Percentiles for the Distribution of Participant Values: The graph provided for each measure contains information about the distribution of the value of the measure across all STS participants, namely the minimum, maximum, 10th percentile, 50th percentile, and 90th percentile. The “Xth” percentile, denoted \( P_x \), is loosely defined as the number having the property that \( X \% \) of the participant values are less than \( P_x \), and \( (100 – X) \% \) of the participant values are greater than \( P_x \). For process measures, participants with greater than 5% missing data were excluded when calculating percentiles of the STS distribution and do not have a calculated participant percentile. For participants having less than 5% missing data on a process measure, the missing values on the process measure were converted to “No” before calculating percentiles. For outcomes measures, all participants submitting at least one eligible case were included when calculating percentiles of the STS distribution. Missing data on outcomes variables were treated as “No.”

NQF/STS Results Comparison: Participants may see some differences between summaries of their data provided in the NQF section of the report and summaries of their data reported elsewhere in the STS report. These differences are due to subtle variations in variable definitions, patient inclusion and exclusion criteria, and rules for handling missing data in the NQF section versus the rest of the report. Definitions used in the NQF report were designed to match current NQF specifications as closely as possible. It is expected that these differences will eventually disappear as the NQF measures are refined. Some important differences are:

Case Volumes – The NQF report section presents “annualized” volumes. These are case volumes that have been adjusted for the number of months that a participant was an active contributor to the database. Elsewhere in the STS report, total case volumes are presented without adjustment for the length of participation.

Eligible Cases - The NQF report also presents the number of “eligible cases” for each measure. Separate inclusion criteria are applied to each measure, and these inclusion criteria do not always match the definitions used elsewhere in the STS report. Please refer to the footnotes in each section for specific details.

Interpretation Manual
In addition to the statistics provided for each of the STS Composite Quality Domains and NQF measures, a figure representing the distribution of values for the entire STS population is provided.

The figure allows participants to quickly judge their performance relative to the overall STS. The scale of the figure is set up such that the right side of the distribution represents the most favorable performance and the left side represents the least favorable performance (Note that in some cases smaller numbers will be on the left; in other instances, smaller numbers will be on the right. For example, for the Pre-operative Beta Blockade Therapy measure, the far left side of the distribution will contain the lowest percentage Beta Blockade Therapy for an STS participant – this corresponds to least favorable performance. Alternatively, for the Operative Mortality Measure, the far left side of the distribution will contain the highest Estimated Odds Ratio – this also corresponds to least favorable performance). If a participant’s value for a given measure is to the left of the STS overall value, the participant is performing worse on that measure than the overall STS. Conversely, if the participant’s value for a given measure is located to the right of the overall STS value, the participant is performing better than the overall STS.

**NOTE!** Care should be given to reading these figures. In some instances, the various percentiles presented cluster very close together in the data. In such cases, the label for the percentile is not necessarily located immediately at the point on the distribution where the percentile occurs. An example of this is apparent in the figure above: The 50th percentile corresponds to a value of 93.7 and looks to align fairly closely with the STS overall value as represented by the large black dot. However, the expandable figure marking actually points to a place somewhere to the right of the STS overall value for the 50th percentile marking. So the STS overall value would be some amount less than 93.7.

Also, please note that in some cases, small sample sizes preclude valid comparisons between the participant and the STS overall. Such instances are clearly noted in the report output.

**a. NQF Measures Interpretation Example**

Sample CABG Operative Mortality results – tabular and figure representation.

<table>
<thead>
<tr>
<th>NQF Measure</th>
<th>Eligible Procedures</th>
<th>Participant Estimated OR</th>
<th>Participant Percentile</th>
<th>Participant Observed Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005 CABG Operative Mortality</td>
<td>74</td>
<td>1.14</td>
<td>26.3</td>
<td>5.4%</td>
</tr>
</tbody>
</table>
Eligible Procedures: 74 patients met the inclusion criteria for the indicated measure.

Participant Estimated OR (Odds Ratio): The main summary statistic measuring the impact that a participant’s performance has on a patient’s probability of experiencing an adverse outcome has a value of 1.14 indicating worse than expected performance.

Participant Percentile: 26.3% of STS participants had an estimated OR greater than or equal to your estimated OR. In other words, 26.3% had the same or worse performance.

Participant Observed Rate: 5.4% of the 74 eligible patients experienced the specified outcome.

2005 CABG Operative Mortality

The highest OR among all STS participants = 2.29
The lowest OR among all STS participants = 0.45
The STS average OR is 1.00
The 95% confidence interval for the participant’s OR spans from <0.45 to ~1.90

2) Sample page from section of the report that contains NQF measure results:
<table>
<thead>
<tr>
<th>NOF Measure</th>
<th>Eligible Procedures</th>
<th>Participant Usage (95% CI)</th>
<th>Participant Percentile</th>
<th>Overall STS Usage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan 2009 - Dec 2009 Preoperative Beta Blockade Therapy¹</td>
<td>541</td>
<td>89.3% (86.4%, 91.8%)</td>
<td>60.9%</td>
<td>82.1%</td>
</tr>
<tr>
<td>Jan 2009 - Dec 2009 Use of IMH²</td>
<td>536</td>
<td>96.5% (94.5%, 97.9%)</td>
<td>63.3%</td>
<td>94.2%</td>
</tr>
<tr>
<td>Jan 2008 - Dec 2008 Discharge Anti-Platelet Medication²</td>
<td>536</td>
<td>98.7% (97.3%, 99.5%)</td>
<td>68.7%</td>
<td>98.1%</td>
</tr>
<tr>
<td>Jan 2009 - Dec 2009 Discharge Bets Blockade Therapy³</td>
<td>538</td>
<td>96.1% (94.1%, 97.6%)</td>
<td>53.4%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Jan 2008 - Dec 2008 Discharge Anti-Lipid Treatment⁴</td>
<td>535</td>
<td>91.8% (89.1%, 94.0%)</td>
<td>40.7%</td>
<td>91.4%</td>
</tr>
</tbody>
</table>

¹ Excludes 2.61 contraindicated / not indicated records.
² Excludes patients with prior CAGS surgery.
³ Anti-platelet use includes Lasor and ACP inhibitors, and excludes in-hospital mortality. Excludes v2.61 contraindicated / not indicated records.
⁴ Excludes in-hospital mortality. Excludes v2.61 contraindicated / not indicated records.

NOF Measures -- 4